Padsevonil Suppresses Seizures Without Inducing Cell Death in Neonatal Rats

Overview

Journal Pharmacol Rep

Specialty Pharmacology

Date 2024 Jul 19

PMID 39028384

Authors

Sean Quinlan

Eric Witherspoon

Patrick A Forcelli

Affiliations

Soon will be listed here.

Abstract

Background: Padsevonil (PSL) is a rationally designed anti-seizure medication (ASM) which has overlapping mechanisms of action with the two most common ASMs used for neonatal seizures, phenobarbital (PB) and levetiracetam (LEV). Here we evaluated the anti-seizure properties of PSL across the neonatal and adolescent period in rats in the pentlyenetetrazole (PTZ) induced seizures model.

Methods: Postnatal day (P)7, P14 and P21 Sprague-Dawley rat pups were pre-treated with PSL (1-30 mg/kg), and assessed for seizure latency and severity 30 min later following injection of PTZ. A separate cohort of P7 pups were treated with neonatal ASMs and euthanized 24 h later (on P8) to assess induction of cell death, a feature common to many ASMs when given to P7 rodents. This effect has been extensively reported with PB, but not with LEV. Cell death was assessed by PathoGreen staining.

Results: PSL suppressed PTZ-evoked seizures across multiple age groups, particularly at higher doses, without producing increased cell death compared to vehicle. The effects of PSL were particularly notable at suppressing tonic-clonic seizure manifestations (82% of P7 and 100% of P14 and P21 animals were protected from tonic-clonic seizures with the 30 mg/kg dose).

Conclusions: PSL displayed dose-dependent anti-seizure effects in immature rodents in the PTZ model of seizures in immature rats. While many ASMs, including PB, induce cell death in neonatal rats, PSL does not. This suggests that PSL may offer therapeutic benefit and a favorable safety profile for the treatment of neonatal seizures.

References

Velisek L, Kulhankova I, Roztocilova L, Mares P, Veliskova J, Mirvaldova H . Ethosuximide affects both pentylenetetrazole- and kainate-induced clonic seizures but differentiates between tonic-clonic seizures. Can J Physiol Pharmacol. 1989; 67(10):1357-61. DOI: 10.1139/y89-216. View

Sharpe C, Reiner G, Davis S, Nespeca M, Gold J, Rasmussen M . Levetiracetam Versus Phenobarbital for Neonatal Seizures: A Randomized Controlled Trial. Pediatrics. 2020; 145(6). PMC: 7263056. DOI: 10.1542/peds.2019-3182. View

Bittigau P, Sifringer M, Genz K, Reith E, Pospischil D, Govindarajalu S . Antiepileptic drugs and apoptotic neurodegeneration in the developing brain. Proc Natl Acad Sci U S A. 2002; 99(23):15089-94. PMC: 137548. DOI: 10.1073/pnas.222550499. View

Matagne A, Margineanu D, Kenda B, Michel P, Klitgaard H . Anti-convulsive and anti-epileptic properties of brivaracetam (ucb 34714), a high-affinity ligand for the synaptic vesicle protein, SV2A. Br J Pharmacol. 2008; 154(8):1662-71. PMC: 2518465. DOI: 10.1038/bjp.2008.198. View

Haugvicova R, Kubova H, Skutova M, Mares P . Anticonvulsant action of topiramate against motor seizures in developing rats. Epilepsia. 2000; 41(10):1235-40. DOI: 10.1111/j.1528-1157.2000.tb04600.x. View

Loscher W . Critical review of current animal models of seizures and epilepsy used in the discovery and development of new antiepileptic drugs. Seizure. 2011; 20(5):359-68. DOI: 10.1016/j.seizure.2011.01.003. View

Wood M, Daniels V, Provins L, Wolff C, Kaminski R, Gillard M . Pharmacological Profile of the Novel Antiepileptic Drug Candidate Padsevonil: Interactions with Synaptic Vesicle 2 Proteins and the GABA Receptor. J Pharmacol Exp Ther. 2019; 372(1):1-10. DOI: 10.1124/jpet.119.261149. View

Witherspoon E, Quinlan S, Forcelli P . Preclinical efficacy of cannabidiol for the treatment of early-life seizures. Pharmacol Rep. 2022; 74(5):1092-1098. PMC: 10694641. DOI: 10.1007/s43440-022-00413-9. View

Talos D, Chang M, Kosaras B, Fitzgerald E, Murphy A, Folkerth R . Antiepileptic effects of levetiracetam in a rodent neonatal seizure model. Pediatr Res. 2012; 73(1):24-30. PMC: 6745697. DOI: 10.1038/pr.2012.151. View

10.

Verwoerd C, Limjoco J, Rajamanickam V, Knox A . Efficacy of Levetiracetam and Phenobarbital as First-Line Treatment for Neonatal Seizures. J Child Neurol. 2022; 37(5):401-409. DOI: 10.1177/08830738221086107. View

11.

Velisek L, Veresova S, Pobisova H, Mares P . Excitatory amino acid antagonists and pentylenetetrazol-induced seizures during ontogenesis. II. The effects of MK-801. Psychopharmacology (Berl). 1991; 104(4):510-4. DOI: 10.1007/BF02245658. View

12.

Kanmaz S, Altun Koroglu O, Terek D, Serin H, Simsek E, Cetin I . Efficacy of levetiracetam as first-line therapy for neonatal clinical seizures and neurodevelopmental outcome at 12 months of age. Acta Neurol Belg. 2020; 121(6):1495-1503. DOI: 10.1007/s13760-020-01366-7. View

13.

Velisek L, Kubova H, Pohl M, StankovA L, Mares P, Schickerova R . Pentylenetetrazol-induced seizures in rats: an ontogenetic study. Naunyn Schmiedebergs Arch Pharmacol. 1992; 346(5):588-91. DOI: 10.1007/BF00169017. View

14.

Huizenga M, Forcelli P . Neuroprotective Action of the CB1/2 Receptor Agonist, WIN 55,212-2, against DMSO but Not Phenobarbital-Induced Neurotoxicity in Immature Rats. Neurotox Res. 2018; 35(1):173-182. PMC: 6318010. DOI: 10.1007/s12640-018-9944-9. View

15.

Haugvicova R, Kubova H, Mares P . Does vigabatrin possess an anticonvulsant action against pentylenetetrazol-induced seizures in developing rats?. Physiol Res. 2002; 51(4):363-70. View

16.

Forcelli P, Janssen M, Stamps L, Sweeney C, Vicini S, Gale K . Therapeutic strategies to avoid long-term adverse outcomes of neonatal antiepileptic drug exposure. Epilepsia. 2010; 51 Suppl 3:18-23. PMC: 3048842. DOI: 10.1111/j.1528-1167.2010.02603.x. View

17.

Forcelli P, Soper C, Lakhkar A, Gale K, Kondratyev A . Anticonvulsant effect of retigabine during postnatal development in rats. Epilepsy Res. 2012; 101(1-2):135-40. DOI: 10.1016/j.eplepsyres.2012.03.006. View

18.

Al-Muhtasib N, Sepulveda-Rodriguez A, Vicini S, Forcelli P . Neonatal phenobarbital exposure disrupts GABAergic synaptic maturation in rat CA1 neurons. Epilepsia. 2018; 59(2):333-344. PMC: 6364562. DOI: 10.1111/epi.13990. View

19.

Maitre N, Smolinsky C, Slaughter J, Stark A . Adverse neurodevelopmental outcomes after exposure to phenobarbital and levetiracetam for the treatment of neonatal seizures. J Perinatol. 2013; 33(11):841-6. PMC: 4000307. DOI: 10.1038/jp.2013.116. View

20.

Bittigau P, Sifringer M, Ikonomidou C . Antiepileptic drugs and apoptosis in the developing brain. Ann N Y Acad Sci. 2003; 993:103-14; discussion 123-4. DOI: 10.1111/j.1749-6632.2003.tb07517.x. View